

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1548)**

## **VOLUNTARY ANNOUNCEMENT RESEARCH AND DEVELOPMENT UPDATE**

Reference is made to the voluntary announcements of Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 28 October 2016, 14 May 2017 and 6 June 2017 in relation to the research and development results of chimeric antigen receptor T (“**CAR-T**”) cell technology in immunotherapy for cancer cure by Nanjing Legend Biotechnology Co., Ltd.\* 南京傳奇生物科技有限公司 (“**Nanjing Legend**”), a wholly-owned subsidiary of the Company as of the date of this announcement.

As of 18 September, 2017, Nanjing Legend collaborated with four 3A hospitals in China for clinical research and applied its proprietary CAR-T technology, and treated 71 relapsed or refractory multiple myeloma patients. 40 of the treated patients were followed up for at least three months, among which 24 patients achieved “complete response”, 12 achieved “very good partial response”, three achieved “partial response” and one unreported response as the relevant patient dropped out of the clinical research. Among all the treated patients, 66 patients experienced different levels of cytokine release syndrome.

One patient who was treated at a collaborating partner hospital in Shanghai (the “**Hospital**”), regrettably, passed away on 16 September 2017 (the “**Incident**”). Upon knowledge of the Incident, the Group (i) immediately noticed all the trial investigators at the other three collaborating partner hospitals, (ii) reported the Incident to the ethical committee at the Hospital and (iii) launched an investigation into the cause of the death (the “**Investigation**”). The Group aims to deliver a preliminary report on the Investigation to all trial investigators in approximately seven days. The Group will closely monitor the situation and development and, issue further announcement(s) with respect to the Investigation in due course.

Based on the clinical research data as of 18 September 2017 as aforementioned, despite the Incident, the Group believes the CAR-T cell technology has potential in clinical cancer therapeutics and continues to utilize the clinical research data to develop the CAR-T cell technology.

By order of the Board  
**Genscript Biotech Corporation**  
**Dr. Zhang Fangliang**  
*Chairman and Chief Executive Officer*

Hong Kong, 19 September 2017

*As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Huang Zuie-Chin and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.*

\* *For identification purposes only*